|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
| about
immune-based therapies, and how they are being applied to try to stimulate
immunity in chronic viral infections due to HIV and HCV |
|
| Dr. Kendall Smith's HIV
& HCV Interleukin 2 Resource Site |
|
|
|
|
|
|
|
|
|
 |
| about HIV & HCV clinical
trials incorporating immunotherapy and how you and your physician
can participate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
| your
knowledge with late-breaking news of immunotherapy research by launching
your own web search |
|
|
|
|
|
|
|
|
|
|
|
| Dr. Kendall A. Smith is
the Rochelle Belfer Professor of Medicine and Immunology at Cornell
University's Weill Medical College and Graduate School of Biomedical
Sciences. He is also Senior Attending Physician and Chief of the Division
of Immunology at The New York Presbyterian Medical Center. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
| further by reading Dr. Smith's
conference papers, presentations and published
materials online |
|
|
|
|
|
|
|
|
|
 |
|
| links
to IL-2 immunotherapy news |
|
|
|
Dr. Smith's
research team created the first monoclonal T cells, which enabled
them to first identify and characterize the interleukin 2 molecule
and the interleukin 2 receptor. These advances led them to develop
interleukin 2 as a therapeutic agent in low daily nontoxic doses,
which they are now testing together with therapeutic
vaccines for the treatment of chronic
viral infections such as HIV and
hepatitis C. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
about the history of the discovery
of interleukin-2 |
|
|
|
|
|
 |
|
| The New
York Presbyterian Hospital Cornell Medical Center |
|
|
|
|
 |
|
| this page to a friend or colleague
who may not know about this breakthrough
research |
|
|
© Kendall A. Smith, 2002 |
|
|
|
|
|
|
![[CNW:Counter]](http://counter.cnw.cz/linda.cgi?kasmith&5&FFFFFF&000000&on)
|
 |
|
| Dr. Smith
directly for further information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|